Furthermore, Stx2 and LPS treatment activates coagulation/fibrinogenesis pathways, as indicated by increased plasma thrombin-antithrombin III (TAT) complex, fibrinogen and plasminogen activator inhibitor-1(PAI-1) levels and decreased platelet counts [9], [23], all of which have also been detected in human HUS patients [25], [26], [27]. The gene discussed is SERPINE1; the disease is hemolytic-uremic syndrome.